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ABSTRACT Heart failure is accompanied by severely im-
paired b-adrenergic receptor (bAR) function, which includes
loss of bAR density and functional uncoupling of remaining
receptors. An important mechanism for the rapid desensitization
of bAR function is agonist-stimulated receptor phosphorylation
by the bAR kinase (bARK1), an enzyme known to be elevated in
failing human heart tissue. To investigate whether alterations in
bAR function contribute to the development of myocardial
failure, transgenic mice with cardiac-restricted overexpression of
either a peptide inhibitor of bARK1 or the b2AR were mated into
a genetic model of murine heart failure (MLP2y2). In vivo cardiac
function was assessed by echocardiography and cardiac cathe-
terization. Both MLP2y2 and MLP2y2yb2AR mice had enlarged
left ventricular (LV) chambers with significantly reduced frac-
tional shortening and mean velocity of circumferential fiber
shortening. In contrast, MLP2y2ybARKct mice had normal
LV chamber size and function. Basal LV contractility in the
MLP2y2ybARKct mice, as measured by LV dPydtmax, was
increased significantly compared with the MLP2y2 mice but less
than controls. Importantly, heightened bAR desensitization in
the MLP2y2 mice, measured in vivo (responsiveness to isopro-
terenol) and in vitro (isoproterenol-stimulated membrane adeny-
lyl cyclase activity), was completely reversed with overexpression
of the bARK1 inhibitor. We report here the striking finding that
overexpression of this inhibitor prevents the development of
cardiomyopathy in this murine model of heart failure. These
findings implicate abnormal bAR-G protein coupling in the
pathogenesis of the failing heart and point the way toward
development of agents to inhibit bARK1 as a novel mode of
therapy.
One of the most important mechanisms for rapidly regulating
b-adrenergic receptor (bAR) function is agonist-stimulated re-
ceptor phosphorylation by G protein-coupled receptor kinases
(GRKs) resulting in decreased sensitivity to further catechol-
amine stimulation (1, 2). bARK1 is a member of the multigene
GRK family that regulates a wide variety of receptors that couple
to heterotrimeric G proteins (1, 2). Desensitization of agonist-
occupied receptors by the cytosolic bAR kinase (bARK1) re-
quires a membrane-targeting event before its activation and
receptor phosphorylation, which is mediated by a direct physical
interaction between residues within the carboxyl terminus of
bARK1 and the dissociated membrane-anchored bg subunits of
G proteins (Gbg) (3, 4).
Heart failure is a disease characterized by left ventricular (LV)
dysfunction associated with a complex of symptoms that relate to
inadequate perfusion of tissues and pulmonary congestion. Al-
though the fundamental molecular abnormality that causes this
progressive deterioration in cardiac function is unknown, one of
the leading candidates is abnormal bAR signaling. Chronic
human heart failure is characterized by severely attenuated bAR
signaling, resulting from diminished receptor number and im-
paired receptor function (5), leading to inotropic subsensitivity
and impaired exercise tolerance (6). Increased levels of bARK1,
found in failing human heart tissue, have been postulated to
account for impaired receptor function in response to agonist
stimulation (7, 8). In animal models of heart disease, prominent
bAR desensitization recently has been shown to be associated
with heightened levels of bARK1 (9, 10). Our findings in trans-
genic mice that overexpress different members of the GRK family
demonstrate how the up-regulation of bARK1 in the diseased
heart could markedly alter bAR function through receptor
desensitization (9, 11, 12). Importantly, inhibition of myocardial
bARK1 activity because of cardiac-targeted expression of a
peptide inhibitor of bARK1 (bARKct) led to enhanced contrac-
tility demonstrating the critical role of bARK1 in normal heart
function (11). The bARKct is composed of the last 195 aa of
bARK1, which contains the binding site for Gbg and competes
with endogenous bARK1 for Gbg membrane translocation and
activation (11).
A limitation in addressing mechanistic pathways in the setting
of heart failure has been the lack of a well characterized model
of murine heart failure that has fidelity to the human condition
(13). Recently, a genetic model of murine-dilated cardiomyopa-
thy has been described that involves ablation of a muscle-
restricted gene that encodes the muscle LIM protein (MLP2y2)
(14). Our goal was to determine whether abnormalities in bAR
signaling in the failing heart play a causative role in the progres-
sive deterioration in cardiac function and whether reversal of
these alterations can lead to improvement of cardiac function. To
accomplish this, our strategy was to mate transgenic mice with
cardiac-targeted overexpression of either the bARKct (11) or the
b2AR (15) into the MLP2y2 model of heart failure.
METHODS
Experimental Animals. MLP2y2 mice were mated with trans-
genic mice with cardiac-targeted overexpression of the bARKct
(11). F1 pups generated from an MLP2y2 3 bARKct(tyt)
homozygote cross were mated to create the MLP1y2y
bARKct(ty0) double heterozygote (where t represents the pres-
ence of a transgene). F2 offspring generated from a MLP2y2 3
MLP1y2ybARKct(ty0) double heterozygote mating generated
mice that were MLP2y2 and MLP2y2ybARKct(ty0) with the
remainder of the pups heterozygous for MLP with and without
the bARKct transgene. F3 offspring were generated by back-
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crossing a MLP2y2ybARKct(ty0) mouse into the MLP2y2 par-
ent to generate MLP2y2 and MLP2y2ybARKct(ty0) littermates.
A similar strategy was used to generate MLP2y2yb2AR(ty0)
gene-targeted mice. The genotype of the various gene-targeted
crosses was determined by PCR on genomic DNA isolated from
tail biopsies as described previously (11, 14, 15). Expression of the
bARKct peptide in hearts of MLP2y2ybARKct mice was con-
firmed by immunoblotting using a polyclonal antibody directed
against the C terminus of bARK1. The animals in this study were
handled according to approved protocols and the animal welfare
regulations of the University of North Carolina at Chapel Hill,
Duke University, and the University of California at San Diego.
Transthoracic Echocardiography. Echocardiography was per-
formed in anesthetized mice (2.5% avertin, 14 mlyg intraperito-
neally) by using an Apogee CX echocardiograph (Interspec-ATL,
Bothell, WA) as described previously (16). Echocardiography was
performed in nonlittermate control MLP1y1 mice by using a
different anesthesia (mixture of 100 mgykg ketamine and 5 mgykg
xylazine, i.p.), which is associated with a lower heart rate and
therefore mean velocity of circumferential fiber shortening
(mean Vcf) (16).
Cardiac Catheterization. Hemodynamic evaluation in intact
mice was performed as described previously (9). Mice were
anesthetized with a mixture of ketamine (100 mgykg) and xyla-
zine (2.5 mgykg) and, after endotracheal intubation, were con-
nected to a rodent ventilator. After bilateral vagotomy, the left
carotid artery was cannulated with a flame-stretched PE-50
catheter connected to a modified P-50 Statham transducer (17).
A 1.4 French (0.46 mm) high-fidelity micromanometer catheter
(Millar Instruments, Houston, TX) was inserted into the right
carotid and advanced retrograde into the LV. Hemodynamic
measurements were recorded at baseline and 45–60 sec after
injection of incremental doses of isoproterenol (9).
Adenylyl Cyclase Activity and bAR Binding. Adenylyl cyclase
activity and bAR binding were performed from myocardial
sarcolemmal membranes (9, 11). For cyclase activity, membranes
(30–40 mg protein) were incubated for 15 min at 37°C with
[a -32P]ATP under basal conditions or indicated agonists and
cAMP was quantified (9, 11). Total b AR density was determined
by incubating 25 mg of sarcolemmal membranes with a saturating
concentration of [125I]cyanopindolol and 20 mM alprenolol to
define nonspecific binding (9, 11).
Immunoblotting. Immunodetection of myocardial levels of
bARK1 was performed on cytosolic extracts after immunopre-
cipitation by using a monoclonal bARK1y2 antibody as described
previously (9, 11, 18). The '80-kDa bARK1 protein was visu-
alized with the mAb raised against an epitope within the carboxyl
terminus of bARK1 and chemiluminescent detection of anti-
mouse IgG conjugated with horseradish peroxidase (ECL, Am-
ersham). GRK activity was measured in myocardial membranes
by using rhodopsin-enriched rod outer segment membranes as an
in vitro substrate and [g-32P]ATP as described previously (9, 11,
18). [32P] incorporation into rhodopsin was quantified by using a
using a Molecular Dynamics PhosphorImager (9, 11, 18).
Histological Analysis of Gene-Targeted Mouse Hearts. Un-
fixed myocardial cryosections were obtained and histological
staining of myocytes was done with Masson’s trichrome by
standard protocols (14).
Statistical Analysis. Data were expressed as mean 6 SEM. To
test for statistical differences in echocardiographic data between
all groups, a one-factor ANOVA was performed accompanied by
a Newman–Keuls post hoc analysis when appropriate. Hemody-
namic data were analyzed with a repeated-measures ANOVA,
and post hoc analysis with regard to differences in mean values
between the groups at a specific dose was conducted with a
Newman–Keuls test. Cyclase activity was analyzed with a repeat-
ed-measures ANOVA. bAR density and NaF stimulation were
determined with a one-factor ANOVA. A Student’s t test was
used to test differences in the level of myocardial bARK1.
RESULTS
To investigate whether abnormalities in bAR signaling are re-
sponsible for the progressive deterioration in cardiac function in
the failing heart, we used a strategy whereby transgenic mice with
cardiac-targeted overexpression of either the bARKct (11) or the
b2AR (15) were mated into the MLP2y2 model of heart failure.
In vivo cardiac function in these novel, dual gene-targeted mice
was assessed by echocardiography. MLP2y2 mice have enlarged
cardiac chambers with depressed function as shown by the
increase in LV end-diastolic and end-systolic dimension associ-
ated with a reduction in fractional shortening (FS) and mean Vcf
(Table 1 and Fig. 1A). Cardiac overexpression of the b2AR in the
MLP-deficient background did not influence the development of
the dilated cardiomyopathic phenotype, because cardiac cham-
bers remained enlarged whereas FS and mean Vcf continued to
be depressed compared with MLP2y2 littermates (Table 1 and
Fig. 1A). In striking contrast, cardiac-targeted bARK1 inhibition
through overexpression of the bARKct prevented the deteriora-
Table 1. Transgene overexpression in MLP-deficient mice: In vivo echocardiographic assessment
MLP2y2a,
n 5 12
MLP2y2yb2AR,
n 5 9
MLP2y2b,
n 5 7
MLP2y2ybARKct,
n 5 9
MLP1y1,
n 5 16
LVEDD, mm 4.86 6 0.29 4.78 6 0.27 4.89 6 0.24 3.74 6 0.22† 3.94 6 0.09†
LVESD, mm 3.84 6 0.30 3.94 6 0.31 3.97 6 0.28 2.43 6 0.22* 2.47 6 0.08*
FS, % 22.3 6 2.3 18.5 6 3.6 19.3 6 2.2 35.8 6 2.4* 37.4 6 1.2*
SEPth, mm 0.67 6 0.04 0.56 6 0.05 0.56 6 0.03 0.59 6 0.04 0.67 6 0.02
PWth, mm 0.66 6 0.04 0.58 6 0.05 0.58 6 0.04 0.58 6 0.05 0.68 6 0.02
HR, beatsymin 437 6 28 517 6 44 483 6 36 474 6 28 258 6 12‡
mean Vcf, circys 4.06 6 0.35 3.74 6 0.65 4.11 6 0.57 7.73 6 0.81* 4.64 6 0.20‡
mean Vcfc, circys 1.51 6 0.14 1.32 6 0.21 1.48 6 0.22 2.88 6 0.25* 2.24 6 0.12*‡
BW, g 36.3 6 3.0 34.2 6 2.5 33.6 6 1.7 29.9 6 1.8 33.8 6 1.8
Mean age at echo, months 7.3 6 0.8 5.1 6 0.7 5.3 6 0.1 6.9 6 0.7 3.4 6 0.1
Analysis of in vivo cardiac size and function by echocardiography in gene-targeted mice. Mating of transgenic mice with cardiac overexpression
of the b2AR or a a bARKct into the MLP-deficient background resulted in mice homozygous for the MLP gene ablation and heterozygous for
either the b2AR (MLP2y2yb2AR) or the bARKct (MLP2y2ybARKct), MLP2y2a and MLP2y2b are littermates for the b2AR and bARKct cross,
respectively. MLP1y1 are adult nonlittermate wild-type mice of the same genetic background that were used as controls. LVEDD, left ventricular
end diastolic dimension; LVESD, left venrtricular end systolic dimension; HR, heart rate; FS, fractional shortening calculated as (LVEDD 2
LVESD)yLVEDD 3 100; SEPth, septal wall thickness; PWth, posterior wall thickness; mean Vcf, mean velocity of circumferential fiber shortening;
mean Vcfc, heart rate-corrected mean Vcf; BW, body weight. *P , 0.0005, †P , 0.01, MLP2y2ybARKct and MLP1y1 vs. either MLP2y2b or
MLP2y2a; ‡P , 0.01, MLP(1y1) vs. MLP2y2ybARKct. The MLP2y2ybARKct and MLP2y2a mice were significantly older than the other groups.
(P , 0.05). MLP1y1 mice underwent echocardiography with a different anesthesia, accounting for the slower heart rate and therefore a lower mean
Vcf (16). However, for the echocardiographic parameters measured, no significant differences in any of the other variables were found between
the MLP2y2yb2AR and their MLP2y2a littermates, or between the MLP2y2a and MLP2y2b littermate groups. Therefore, for subsequent analysis
of echocardiographic data, the MLR2y2 groups were pooled.
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tion in cardiac function (Table 1 and Fig. 1A). In MLP2y2y
bARKct mice compared with age-matched MLP2y2 littermates,
LV end-diastolic and end-systolic dimensions were significantly
smaller, whereas FS and mean Vcf were significantly higher,
indicating preserved cardiac function (Table 1 and Fig. 1A).
To determine whether changes in ventricular function were
time-dependent, serial echocardiography was performed in
the three groups of gene-targeted mice. MLP2y2 mice and
MLP2y2yb2AR under 6 months of age have enlarged LV cham-
bers with depressed cardiac function (reduced FS and mean Vcfc)
(Fig. 1B). In contrast, MLP2y2ybARKct mice under 6 months of
age have normal LV chamber size and function (Fig. 1B). This
beneficial effect of the bARKct on cardiac function persisted as
the mice grew older, whereas little change and even some
deterioration occurred in the MLP2y2 and MLP2y2yb2AR mice
(Fig. 1B). Individual data points are plotted for FS to determine
whether a serial change in cardiac function occurred over a
3-month period (Fig. 1C). Whereas MLP2y2 animals had re-
duced FS that did not change over time, the presence of addi-
tional cardiac b2ARs (MLP2y2yb2AR) resulted in deterioration
of FS in the majority of mice. In contrast, FS was preserved in the
MLP2y2ybARKct mice and remained in the normal range over
the 3-month study interval (Fig. 1C).
To determine whether overexpression of the bARKct can
reverse the marked bAR desensitization associated with the
MLP2y2 mice, we performed cardiac catheterization in intact
anesthetized mice. LV contractility (assessed by LV dPydtmax) at
baseline in the MLP2y2ybARKct mice was modestly but signif-
icantly increased compared with the MLP2y2, but was less than
nonlittermate wild-type MLP1y1 control mice (Fig. 2A). How-
ever, the abnormal response to isoproterenol stimulation, char-
acteristic of the MLP2y2 animals, was reversed completely with
bARKct overexpression (Fig. 2 A and B). This response to
isoproterenol was essentially identical to that in the wild-type
MLP1y1 mice and is consistent with a mechanism of bARK1
inhibition that preserves normal bAR-G protein coupling (Fig. 2
A and B). Similarly, the increase in heart rate from baseline in
response to bAR stimulation was preserved in the MLP2y2y
bARKct mice although basal heart rate was lower than in
wild-type mice (Fig. 2C). Furthermore, the markedly elevated LV
end diastolic pressure in the MLP2y2 mice (an indication of the
severe impairment of cardiac function in these animals) was
normalized by chronic bARKct expression (Fig. 2D). The min-
imal first derivative of LV pressure, LV dPydtmin, also was
enhanced in the MLP2y2ybARKct compared with the MLP2y2
mice at baseline (23,964 6 420 vs. 22,634 6 140, mmHgysec,
P , 0.005) but was significantly less than that in wild-type mice
(27,411 6 986, mmHgys, P , 0.0005). This relationship persisted
with isoproterenol administration (data not shown). Baseline LV
systolic pressure was similar in the MLP2y2ybARKct animals
FIG. 1. Analysis of cardiac function by echocardi-
ography. (A) Transthoracic M-mode echocardio-
graphic tracings in a MLP2y2 (Top), MLP2y2yb2AR
(Middle), and a MLP2y2ybARKct mouse (Bottom).
Left ventricular dimensions are indicated by the double-
sided arrows. EDD, end diastolic dimension; ESD, end
systolic dimension. Both the MLP2y2 and MLP2y2y
b2AR mice have chamber dilatation with reduced wall
motion indicating depressed cardiac function, whereas
chamber size and cardiac function are normal in the
MLP2y2ybARKct mouse. (B) Echocardiographic find-
ings in mice under 6 months of age: MLP2y2 (solid bar,
mean age 4.1 6 0.4 months, n 5 18), MLP2y2yb2AR
(open bar, mean age 4.3 6 0.4 months, n 5 8), and
MLP2y2ybARKct (hatched bar, mean age 4.7 6 0.7
months, n 5 9); and more than 6 months of age:
MLP2y2 (solid bar, mean age 7.0 6 0.5 months, n 5 17),
MLP2y2yb2AR (open bar, mean age 7.3 6 0.7 months,
n 5 3), and MLP2y2ybARKct (hatched bar, mean age
6.9 6 0.77 months, n 5 8). Data represent serial
echocardiograms in the same mouse at different ages
except if the mouse died during the interval between
studies. p, P , 0.005; †, P , 0.01; ‡, P , 0.05
MLP2y2ybARKct vs. MLP2y2 and MLP2y2yb2AR,
one-factor ANOVA. (C) Change in cardiac function
over a 2.5- to 3-month period in the three groups of
gene-targeted mice. #1, early study (mean age, 3.9
months); #2, later study (mean age, 6.4 months). For
comparison, normal values obtained in MLP1y1 mice
are shown in Table 1.
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compared with the MLP2y2 mice (90 6 4 vs. 96 6 4 mmHg),
but was lower than that in the MLP wild-type mice (128 6 10
mmHg). Hemodynamic analysis could not be performed in the
MLP2y2yb2AR mice because survival was considerably short-
ened and did not allow for an adequate number of animals.
bAR density and adenylyl cyclase activity were determined in
cardiac membranes prepared from the various gene-targeted
lines. bAR density was reduced significantly by 54% in the
MLP2y2 compared with wild-type hearts and was associated with
marked attenuation of isoproterenol-stimulated adenylyl cyclase
activity, indicating severe impairment of bAR coupling (Table 2).
Although bAR density also was reduced in MLP2y2ybARKct
compared with wild-type mice, isoproterenol-stimulated adenylyl
cyclase activity was enhanced significantly and intermediate
between wild-type and MLP-deficient mice (Table 2). Impor-
tantly, fold increase in membrane cyclase activity with isoproter-
enol stimulation in the MLP2y2ybARKct hearts was 2.8 vs. 2.6 in
the wild-type hearts and 1.7 in the MLP2y2 hearts, indicating
restitution toward normal G protein coupling. These biochemical
findings are completely concordant with the in vivo data (Fig. 2)
and indicate that the functional uncoupling of bARs seen in the
failing MLP2y2 hearts can be prevented with chronic overex-
pression in vivo of the bARKct. This is also consistent with the LV
weight data obtained after terminal hemodynamic study where a
significant decrease in LV mass in the MLP2y2ybARKct hearts
(n 5 8) compared with MLP2y2 hearts (n 5 15) was observed
(LV weight to tibia length ratio, 6.5 6 0.3 vs. 7.8 6 0.3 mgymm,
P , 0.02). LV mass in the MLP2y2ybARKct hearts was slightly,
but not significantly, higher than that in the control hearts
(MLP1y1, 5.5 6 0.3 mgymm, n 5 6).
FIG. 2. In vivo assessment of b-AR responsiveness. Cardiac
catheterization was performed in intact, anesthetized mice. Parame-
ters are shown at baseline and after progressive infusion of isopro-
terenol in MLP2y2 (E), n 5 15, MLP2y2ybARKct (F), n 5 7, and
wild-type MLP1y1 (h), n 5 6, mice. (A) Maximal first derivative of LV
pressure, LV dPydtmax. (B) The difference from baseline for LV
dPydtmax, DLV dPydtmax. (C) Heart rate. (D) LV end diastolic
pressure. p, P , 0.0005; †, P , 0.01 MLP2y2ybARKct vs. MLP2y2; ‡,
P , 0.005; §, P , 0.05 wild-type MLP1y1 vs. MLP2y2ybARKct. A
significant between-group main effect in response to isoproterenol was
found for LV dPydtmax, P , 0.00001 (A); heart rate, P 5 0.05 (C);
and LV end diastolic pressure, P , 0.05 (D). The pattern of change
between groups was statistically significantly for LV dPydtmax, P ,
0.00001 (A) and DLV dPydtmax, P , 0.00001 (B).
FIG. 3. Assessment of myocardial bARK1 levels and activity. (A)
bARK1 protein levels of myocardial extracts were determined by
protein immunoblotting. Shown is a representative experiment with
two hearts from each gene-targeted mouse. Similar results were
obtained in two more hearts in each group. bARK1 protein levels were
'2-fold higher in the MLP2y2 hearts compared with MLP1y1 hearts
(P , 0.05) whereas myocardial bARK1 levels in the MLP2y2ybARKct
hearts were not significantly different than wild-type hearts. (B)
Rhodopsin-enriched rod outer segment membranes were used as a
substrate for membrane myocardial GRK activity and 32P incorpora-
tion was quantified from dried gels. The data represent a sample size
of four to six hearts in each group. p, P , 0.05 vs. MLP1y1; #, P ,
0.03 vs. MLP2y2.
Table 2. bAR signaling characteristics
bAR density,
fmolymg membrane protein
Adenylyl cyclase activty,
% NaF stimulation
Basal ISO, 1024 M
MLP2y2 16.6 6 1.9, 2.7 6 0.1, 4.5 6 0.7,
n 5 11 n 5 5 n 5 5
MLP2y2ybARKct 23.0 6 5.4, 2.8 6 0.7, 7.8 6 1.5†‡,
n 5 6 n 5 5 n 5 5
MLP1y1 36.0 6 4.3*, 5.2 6 0.6§, 13.4 6 0.7†,
n 5 6 n 5 5 n 5 5
NaF values in pmol per min per mg: MLP2y2, 33.0 6 2.8; MLP2y2ybARKct, 32.8 6 1.6; MLP1y1, 49.7
6 4.8 (P , 0.02, MLP1y1 vs. MLP2y2ybARKct and MLP2y2). *P , 0.02, MLP1y1 vs. MLP2y2ybARKct
and MLP2y2; †P , 0.005, ISO vs. basal for MLP2y2ybARKct and MLP1y1; ‡P , 0.02, ISO
MLP2y2ybARKct vs. ISO MLP1y1 and ISO MLP2y2; §P 5 0.07 basal MLP1y1 vs. basal MLP2y2y
bARKct and basal MLP2y2. ISO, isoproterenol.
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Because bARK1 levels and activity are enhanced in human
heart failure, we sought to determine whether myocardial
bARK1 levels are increased in the MLP2y2 mouse, which could
contribute to the marked bAR uncoupling observed. Myocardial
bARK1 levels were assessed by immunoprecipitation of soluble
heart extracts. Cytosolic bARK1 levels were '2-fold higher in the
hearts of MLP2y2 animals compared with MLP1y1 animals (Fig.
3A). Furthermore, we measured enzyme activity in extracts from
myocardial membranes, because this is where bARK1 exerts its
regulatory actions. We found membrane GRK activity to be
significantly increased and parallel to the protein data (Fig. 3B).
Immunoblotting for a second GRK found in the heart, GRK5,
revealed no difference in expression between the different lines
of mice (data not shown), indicating that the increase in mem-
brane kinase activity can be accounted for by translocated
bARK1 to the membrane. Taken together, these data show that
chronic myocardial expression of the bARKct eliminates devel-
opment of the severe heart failure phenotype and prevents the
up-regulation of bARK1 as demonstrated by both protein im-
munoblotting and GRK activity (Fig. 3 A and B).
The deleterious effects of b2AR overexpression in the MLP2y2
mice is demonstrated further by the marked adverse effect on
survival. Cumulative survival probability for MLP2y2yb2AR
mice (n 5 11) was shortened significantly such that over a
9-month follow-up period the probability of survival was approx-
imately 12% compared with 80% for the MLP2y2 mice (n 5 19;
P , 0.0001, Mantel–Haenszel x2 statistic, MLP2y2yb2AR vs.
MLP2y2). Over the same time period only 1 of 10 MLP2y2y
bARKct mice died, which occurred at 7 months of age, and did
not differ significantly from the MLP2y2 mice. These data clearly
demonstrate that enhancing bAR signaling through marked
overexpression of b2ARs in this murine model of myocardial
failure has deleterious consequences that are accompanied by
persistent cardiac chamber enlargement, progressive deteriora-
tion in cardiac function, and diminished survival. In contrast,
reversal of bAR desensitization through chronic overexpression
of a bARK1 inhibitor essentially prevents the development of
heart failure in MLP2y2 mice.
We also examined the hearts of these gene-targeted mice
histologically and found that the characteristic fibrosis found in
the MLP2y2 hearts (14) did not seem to lessen because of the
presence of the bARKct (Fig. 4). This is not surprising and
suggests that the histopathological changes in the MLP2y2 hearts
are a result of the absence of the cytoskeletal MLP protein and
are not a result of the dilated cardiomyopathy per se.
DISCUSSION
The above echocardiographic and hemodynamic findings sug-
gest that GRK-mediated bAR desensitization plays a causative
role in the development of heart failure in this animal model.
Moreover, they indicate the potential for novel therapeutic
strategies that aim to modulate the activity level of myocardial
bARK1 during the course of the cardiomyopathic process. We
have chosen to use a genetic-based model of dilated cardio-
myopathy through targeted disruption of the muscle LIM
protein gene, which closely resembles the phenotype of human
dilated cardiomyopathy (14). The MLP is a conserved positive
regulator of myogenic differentiation, and recent findings
suggest that it may act as a molecular adapter to promote
protein assembly along the actin-based cytoskeleton. Hearts
from MLP-deficient mice are characterized by marked disrup-
tion of cardiomyocyte architecture (14). Human heart failure
also is a disease of cardiac muscle characterized by alterations
in cardiomyocyte shape (19), cytoskeletal abnormalities (20),
and bAR signaling (5), which supports our use of the MLP-
deficient mouse as a model system to study underlying mech-
anisms in this disease.
Although abnormalities in bAR signaling have been postulated
to promote cardiac dysfunction in the failing heart, other hypoth-
eses have been suggested, which include altered Ca21 availability
(21), impaired ability of the L-type Ca21 channel to activate
sarcoplasmic reticulum Ca21 release (22), and abnormalities in
myocyte cytoskeleton such as microtubular polymerization (23).
Although the precise mode of action by which overexpression of
the bARKct provides this salutary effect is not clear, it is unlikely
to be a result of a nonspecific effect of transgene overexpression
because cardiac overexpression of a b2AR transgene in the
FIG. 4. Histological analysis of gene-targeted mouse hearts. Representative sections stained with Masson’s trichrome are shown from MLP1y1
and MLP2y2 hearts and two MLP2y2ybARKct hearts.
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MLP-deficient background had no effect on the heart failure
phenotype. The strikingly opposite phenotypes observed with
overexpression of the b2AR and overexpression of the bARKct
suggests that marked chronic enhancement of bAR signaling by
markedly increasing receptor number is not sufficient to prevent
deterioration in cardiac function. In contrast, reversal of b1AR
desensitization through overexpression of a bARK1 inhibitor acts
to restore normal G protein coupling of the endogenous uncou-
pled b1ARs. The lack of a beneficial effect with b2AR transgene
overexpression may in part be related to the extraordinarily high
levels of receptor overexpression in those mice (15) or perhaps a
result of different signaling properties of the b2AR compared
with the b1AR (24). Furthermore, b2AR overexpression in this
model leads to constant maximal signaling (15), whereas bARKct
overexpression preserves myocardial bAR responsiveness to en-
dogenous catecholamine stimulation (11). The deleterious effect
of chronic bAR stimulation in the MLP2y2yb2AR mice is
consistent with the experience from clinical studies using oral
inotropic agents in severe heart failure (25). Our data suggest that
restoring normal control of b1AR signaling by inhibiting en-
hanced desensitization is an important mechanism to prevent the
progressive deterioration in cardiac function in this model of
heart failure. Interestingly, it has been shown recently that
treatment with the bAR antagonist, carvedilol, can improve
survival in human heart failure (26). Although the mechanism(s)
is not known, an intriguing basis for this beneficial effect of bAR
antagonism may be the reduction of desensitization through
lowering of bARK1 levels (ref. 10; G.I., E. D. Tomhave, R.J.L.,
and W.J.K., unpublished results).
Because the bARKct peptide inhibits bARK1 activity via
Gbg sequestration, we cannot definitively exclude the possi-
bility that inhibition of other Gbg-dependent pathways con-
tributes to the improved cardiac status of the MLP2y2y
bARKct animals. However, several lines of evidence argue
strongly for inhibition of bARK1 activity being the primary
mechanism. First, the MLP2y2ybARKct mice have increased
bAR-coupling efficiency demonstrated by the increased iso-
proterenol-stimulated adenylyl cyclase activity and in vivo
cardiac function, which clearly suggests inhibition of desensi-
tization, just as would be expected for bARK1 inhibition.
Second, overexpression of the bARKct does not prevent the
development of cardiac hypertrophy in response to pressure
overload but reverses bAR desensitization (9), suggesting that
other signaling pathways critical for the hypertrophic pheno-
type are unaffected by the bARKct. Third, mice heterozygous
for the bARK1 gene deletion, which possess 50% less bARK1
enzyme compared with wild-type animals, have a cardiac
phenotype of enhanced contractility and sensitivity to bAR
agonists (H.A.R., S. A. Akhter, D.-J.C., M. Jaber, R.J.L., M. G.
Caron, and W.J.K. unpublished results) essentially identical to
the bARKct-overexpressing animals (11). Finally, when the
bARKct transgenic mice were crossed into the bARK1 het-
erozygous knockout background, this led to a further enhance-
ment of cardiac function and isoproterenol responsiveness,
which was associated with a stepwise decrement in Gbg-
dependent bARK1 activity (H.A.R., S. A. Akhter, D.-J.C., M.
Jaber, R.J.L., M. G. Caron, and W.J.K. unpublished results).
Other known actions of Gbg (27, 28) such as activation of the
Ik.ach channel, adenylyl cyclase, PLCb1–3, and MAP kinase
appear not to be relevant in this situation. The Ik.ach channel is
located in atrial and not ventricular tissue and would not be
expected to directly alter contractility (27, 29). The isoforms of
adenylyl cyclase that are regulated by Gbg (I, II, IV) are not found
in the heart (28). PLCb is not activated by myocardial bARs (27).
Finally, in vivo activation of MAP kinase does not affect con-
tractility (30). Taken together, these data strongly suggest that the
striking effects of the bARKct indeed are mediated primarily
through bARK1 inhibition and restored bAR coupling and not
through effects on other Gbg-dependent pathways.
We do not, however, currently know whether the beneficial
effect of bARK1 inhibition also is mediated in part through
reduction of desensitization of G protein-coupled receptors other
than bARs such as, for example, the angiotensin (18) or endo-
thelin receptor. However, if this were the case, an opposite result
would be expected. Inhibition of bARK1 by the bARKct would
increase signaling through these pathways, whereas previous
studies have demonstrated the marked benefit of blocking both
angiotensin (31) and endothelin (32) signaling in heart failure.
The evidence we present here demonstrates the critical role
that chronic bAR desensitization plays in the development of
heart failure and the importance of preserving normal bAR
coupling. That the inhibition of a single molecule (bARK1) can
have such a dramatic effect on a cardiac phenotype caused by a
structural abnormality (MLP deficiency) is surprising and indi-
cates that bARK1 inhibition may offer a novel therapeutic target
in heart failure with the potential to have significant impact on
this disease.
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